May 3, 2024
I suggest that it is better to keep your finger on the sell button but, still keep a buy ticket in the other hand
Pre-open Indications: 3 Sell into Strength, 1 Positive and 1 Negative Indications
Sell when you see the greening of the pre-open upside indication
Weak jobs report sends yields lower: U.S. job growth totaled 175,000 in April, much less than expected as Nonfarm payrolls were expected to increase by 240,000 in April while the unemployment rate held at 3.8%.
Never leave an investor uninformed
May 6, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included
6 reported <SAGE, MDXG, ALNY, BPMC, AXGN, RARE)
May 6, 2024
Earnings this week: Ionis Pharmaceuticals (IONS), Agenus (AGEN) on Tuesday, 5/7, Editas Medicine (EDIT), Vericel (VCEL), Lenz Therapeutics (LENZ) on Wednesday, 5/8; BioLife Solutions (BLFS), blue bird bio (BLUE), Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO) on Thursday, 5/9
Let’s not forget about volatility.
News: Cellectis (CLLS +$0.36) clearance from the French Ministry of Economy and satisfaction of AstraZeneca (AZN) completing the additional equity investment of $140M, as previously announced by CLLS on November 1 and 15, 2023
A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.
Never leave an investor uninformed! A trusted source of factual reporting!
May 6, 2024
LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 6 reported <SAGE, MDXG, ALNY, BPMC, AXGN, RARE)
May 2, 2024
A scorecard of earnings releases of covered companies - The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status". 6 of 35
April 12, 2024
Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … < www.hregen.com > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants. “There's just one problem: His patients kept dying.” Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations! Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!
© 2024 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
